systemic infection); a positive urine or serum pregnancy test within 3 days before study drug administration, or currently breastfeeding; scheduled to receive any other chemotherapeutic agent with an emetogenicity level of three or higher on the Hesketh scale from day –2 to day 6,
except on day 1; scheduled to receive any radiation therapy to the abdomen or pelvis from day –5 to day 6; symptomatic primary or metastatic CNS disease; ongoing vomiting, retching, or clinically signifi cant nausea of any cause or a history of anticipatory nausea and vomiting; vomiting or retching within 24 h before the start of moderately emetogenic chemotherapy on day 1 of cycle 1; use of any investigational drugs within 30 days of randomisation; and participation in any other clinical trial.